Hospital
Temple University Hospital, INC
Temple University Hospital, INC was paid $116.55M by Medicaid between Jan 2018 and Dec 2024, across 547 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
33Billing provider infoTEMPLE UNIVERSITY HOSPITAL, INC
PHILADELPHIA, PA 19140
PHILADELPHIA, PA 19140
33aNPI1962579029assigned 11/30/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$116.55M
24GClaims1,303,178
24DCodes billed547
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#1 of 154
Median peer was paid$2.82M
This provider vs. median41×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 901 | $233K | |
| 2019 | 13,726 | $598K | |
| 2020 | 177,847 | $11.55M | |
| 2021 | 449,485 | $40.79M | |
| 2022 | 189,406 | $21.30M | |
| 2023 | 236,054 | $22.95M | |
| 2024incomplete | 235,759 | $19.13M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 89,599 | 85,237 | $23.81M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 80,963 | 77,045 | $20.53M |
| G0378 | Hospital observation service, per hour | 8.5% | 6,244 | 5,753 | $9.96M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.9% | 60,947 | 58,805 | $4.50M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 3.0% | 3,492 | 3,412 | $3.47M |
| J9271 | Injection, pembrolizumab, 1 mg | 2.9% | 1,382 | 1,080 | $3.36M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.6% | 16,056 | 15,069 | $3.03M |
| 99235 | 2.3% | 3,067 | 2,382 | $2.66M | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.2% | 15,261 | 5,677 | $2.53M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.5% | 27,250 | 23,700 | $1.79M |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.5% | 17,439 | 17,096 | $1.77M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.5% | 9,933 | 9,161 | $1.74M |
535 more codes
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.4% | 17,055 | $1.62M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.3% | 1,561 | $1.53M |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 1.2% | 1,051 | $1.37M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 8,910 | $1.28M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.1% | 1,496 | $1.25M |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 22,514 | $1.12M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 5,721 | $1.02M |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 9,548 | $957K |
| 11102 | <1% | 3,475 | $863K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 807 | $754K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 12,227 | $679K |
| J9299 | Injection, nivolumab, 1 mg | <1% | 190 | $662K |
| 95811 | <1% | 930 | $661K | |
| 74183 | <1% | 1,607 | $627K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 6,874 | $572K |
| 97162 | <1% | 2,310 | $547K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,818 | $524K |
| 49083 | <1% | 802 | $494K | |
| 62323 | <1% | 1,164 | $459K | |
| 77386 | <1% | 1,451 | $434K | |
| 76830 | Ultrasound, transvaginal | <1% | 7,275 | $419K |
| 71250 | <1% | 5,715 | $403K | |
| J9312 | Injection, rituximab, 10 mg | <1% | 101 | $389K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 3,810 | $388K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 7,958 | $388K |
| 76642 | <1% | 6,907 | $383K | |
| 36591 | <1% | 4,445 | $381K | |
| 77066 | Tomosynthesis, mammo | <1% | 3,266 | $373K |
| 11104 | <1% | 1,460 | $371K | |
| 17110 | <1% | 1,448 | $371K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,614 | $366K |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 314 | $360K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,221 | $356K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 7,586 | $350K |
| 11900 | <1% | 1,345 | $333K | |
| J9022 | Injection, atezolizumab, 10 mg | <1% | 136 | $321K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12,262 | $308K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 707 | $292K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,288 | $286K |
| 77065 | Tomosynthesis, mammo | <1% | 3,190 | $259K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 42,799 | $258K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 242 | $245K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 6,541 | $245K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,153 | $236K |
| 43235 | <1% | 258 | $222K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 1,707 | $219K |
| J9035 | Injection, bevacizumab, 10 mg | <1% | 115 | $218K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,185 | $217K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 13,859 | $205K |
| 10005 | <1% | 304 | $201K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,079 | $195K |
| 59025 | Fetal non-stress test | <1% | 3,897 | $194K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,676 | $192K |
| 72197 | <1% | 446 | $192K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 773 | $188K |
| 99205 | Prolong outpt/office vis | <1% | 1,722 | $188K |
| 80053 | Comprehensive metabolic panel | <1% | 20,130 | $160K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,399 | $147K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 701 | $147K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,113 | $144K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,149 | $142K |
| 93017 | <1% | 2,307 | $137K | |
| 93970 | <1% | 1,354 | $135K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,016 | $130K |
| J0897 | Injection, denosumab, 1 mg | <1% | 226 | $129K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,223 | $124K |
| 76770 | <1% | 2,302 | $123K | |
| 93451 | <1% | 83 | $122K | |
| 20610 | <1% | 954 | $122K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,055 | $120K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 3,261 | $120K |
| 76813 | <1% | 2,105 | $117K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 2,936 | $116K |
| 74178 | <1% | 429 | $111K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,857 | $110K |
| 76536 | <1% | 1,837 | $109K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,343 | $109K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 46,033 | $108K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13,030 | $107K |
| 97161 | <1% | 453 | $106K | |
| 58558 | <1% | 92 | $105K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,179 | $104K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 9,052 | $103K |
| 77336 | <1% | 2,402 | $102K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 317 | $100K |
| 73221 | <1% | 383 | $99K | |
| 93975 | <1% | 1,091 | $99K | |
| 86833 | <1% | 1,038 | $95K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,178 | $95K |
| 77080 | <1% | 2,019 | $94K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 25,204 | $92K |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 825 | $91K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 16,588 | $91K |
| 94660 | <1% | 822 | $86K | |
| 73564 | <1% | 4,437 | $86K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,723 | $84K |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | <1% | 82 | $81K |
| 72141 | <1% | 309 | $80K | |
| 77062 | <1% | 2,579 | $77K | |
| 78832 | <1% | 149 | $76K | |
| 73630 | <1% | 5,354 | $74K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 814 | $73K |
| 88172 | <1% | 518 | $71K | |
| 94729 | <1% | 2,116 | $69K | |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | <1% | 96 | $68K |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | <1% | 18 | $68K |
| 77334 | <1% | 649 | $65K | |
| 76801 | <1% | 1,271 | $65K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 962 | $64K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 173 | $63K |
| 86832 | <1% | 687 | $63K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 923 | $62K |
| 73030 | <1% | 3,875 | $61K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 98 | $60K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 9,227 | $59K |
| 94726 | <1% | 1,941 | $57K | |
| 72100 | <1% | 2,248 | $57K | |
| 11103 | <1% | 838 | $56K | |
| 76376 | <1% | 5,735 | $55K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 215 | $54K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,639 | $54K |
| 94618 | <1% | 2,149 | $54K | |
| 93976 | <1% | 636 | $54K | |
| 77061 | <1% | 1,868 | $54K | |
| 71271 | <1% | 528 | $54K | |
| 94060 | <1% | 2,114 | $50K | |
| 93923 | <1% | 838 | $50K | |
| 77412 | <1% | 1,044 | $49K | |
| A9270 | Non-covered item or service | <1% | 38,149 | $46K |
| 93880 | <1% | 473 | $46K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 2,914 | $45K |
| 64615 | <1% | 217 | $45K | |
| H0047 | Alcohol and/or other drug abuse services, not otherwise specified | <1% | 926 | $44K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 50 | $44K |
| 74246 | <1% | 839 | $44K | |
| 84703 | <1% | 11,733 | $44K | |
| 96367 | <1% | 2,133 | $42K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 679 | $41K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,734 | $41K |
| 97163 | <1% | 276 | $41K | |
| 96417 | <1% | 988 | $41K | |
| 73610 | <1% | 2,721 | $40K | |
| 93226 | <1% | 1,013 | $40K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 502 | $39K |
| 88173 | <1% | 522 | $39K | |
| 82948 | <1% | 23,507 | $38K | |
| 96415 | <1% | 1,300 | $37K | |
| 91010 | <1% | 298 | $36K | |
| 0002A | <1% | 883 | $35K | |
| OP250 | <1% | 3,577 | $35K | |
| Q3014 | Telehealth originating site facility fee | <1% | 4,865 | $34K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 14,127 | $34K |
| 83735 | <1% | 10,753 | $33K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 611 | $33K |
| 96411 | <1% | 496 | $31K | |
| 93971 | <1% | 536 | $31K | |
| 91034 | <1% | 177 | $31K | |
| 95819 | <1% | 793 | $30K | |
| 72110 | <1% | 1,069 | $30K | |
| 73130 | <1% | 2,635 | $30K | |
| 70486 | <1% | 665 | $29K | |
| 36561 | <1% | 28 | $28K | |
| 93225 | <1% | 1,024 | $27K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,300 | $26K |
| 76818 | <1% | 385 | $26K | |
| 0001A | <1% | 954 | $26K | |
| 77301 | <1% | 37 | $26K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 2,178 | $26K |
| 76820 | <1% | 738 | $24K | |
| 81003 | <1% | 12,968 | $24K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 736 | $23K |
| 93296 | <1% | 1,082 | $23K | |
| 96402 | <1% | 1,014 | $23K | |
| 97116 | <1% | 737 | $23K | |
| 82803 | <1% | 1,890 | $22K | |
| 93456 | <1% | 15 | $21K | |
| 77300 | <1% | 308 | $21K | |
| 10060 | <1% | 210 | $21K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,019 | $21K |
| 84484 | <1% | 13,230 | $21K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 304 | $21K |
| 87631 | <1% | 1,136 | $21K | |
| 78264 | <1% | 185 | $20K | |
| 73560 | <1% | 1,129 | $20K | |
| 0003A | <1% | 706 | $20K | |
| 88313 | <1% | 812 | $19K | |
| 78454 | <1% | 169 | $19K | |
| 85027 | <1% | 6,759 | $19K | |
| 92526 | <1% | 61 | $19K | |
| 76981 | <1% | 412 | $18K | |
| 81025 | <1% | 3,359 | $18K | |
| 70491 | <1% | 213 | $18K | |
| 88177 | <1% | 518 | $17K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 381 | $17K |
| J0185 | Injection, aprepitant, 1 mg | <1% | 528 | $17K |
| 43237 | <1% | 14 | $17K | |
| 64721 | <1% | 26 | $17K | |
| 76775 | <1% | 333 | $17K | |
| 93922 | <1% | 534 | $16K | |
| 97010 | <1% | 1,025 | $16K | |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | <1% | 40 | $15K |
| 73502 | <1% | 860 | $15K | |
| 94010 | <1% | 793 | $14K | |
| 86803 | <1% | 5,931 | $14K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 806 | $14K |
| 97032 | <1% | 208 | $14K | |
| 72050 | <1% | 427 | $14K | |
| 93000 | <1% | 793 | $13K | |
| 92610 | <1% | 92 | $13K | |
| 19083 | <1% | 26 | $13K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 754 | $13K |
| 96401 | <1% | 264 | $12K | |
| 73523 | <1% | 308 | $12K | |
| Q0092 | Set-up portable x-ray equipment | <1% | 3,101 | $12K |
| 76870 | <1% | 293 | $11K | |
| 97035 | <1% | 335 | $11K | |
| 78306 | <1% | 187 | $11K | |
| C1729 | Catheter, drainage | <1% | 95 | $10K |
| 73700 | <1% | 189 | $10K | |
| 73110 | <1% | 1,075 | $10K | |
| 93041 | <1% | 1,333 | $10K | |
| 72131 | <1% | 177 | $10K | |
| 73120 | <1% | 584 | $10K | |
| 64405 | <1% | 57 | $10K | |
| 80365 | <1% | 1,158 | $9K | |
| 97164 | <1% | 81 | $9K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,106 | $9K |
| 74230 | <1% | 293 | $9K | |
| 0072A | <1% | 372 | $9K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 481 | $9K |
| 82962 | <1% | 4,396 | $9K | |
| 86849 | <1% | 881 | $9K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 657 | $9K |
| 73562 | <1% | 452 | $8K | |
| 36430 | <1% | 339 | $8K | |
| 88341 | <1% | 1,615 | $8K | |
| 86850 | <1% | 3,512 | $8K | |
| 72040 | <1% | 416 | $8K | |
| 99024 | <1% | 451 | $8K | |
| 74174 | <1% | 57 | $7K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 3,118 | $7K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,665 | $7K |
| 73590 | <1% | 664 | $7K | |
| 29125 | <1% | 45 | $7K | |
| 45390 | <1% | 19 | $7K | |
| 38222 | <1% | 18 | $6K | |
| 88312 | <1% | 267 | $6K | |
| 72070 | <1% | 273 | $6K | |
| 76882 | <1% | 340 | $6K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,068 | $6K |
| 36600 | <1% | 471 | $6K | |
| 92611 | <1% | 144 | $6K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 106 | $6K |
| 72114 | <1% | 214 | $6K | |
| 70544 | <1% | 27 | $6K | |
| 80361 | <1% | 1,020 | $6K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 568 | $6K |
| 0004A | <1% | 379 | $5K | |
| 78315 | <1% | 53 | $5K | |
| 86900 | <1% | 3,911 | $5K | |
| 88185 | <1% | 22 | $5K | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 313 | $5K |
| 74420 | <1% | 54 | $5K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 108 | $5K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,047 | $5K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 240 | $5K |
| 72156 | <1% | 17 | $5K | |
| 70498 | <1% | 45 | $5K | |
| 87040 | <1% | 849 | $5K | |
| 86901 | <1% | 3,891 | $5K | |
| 85610 | <1% | 3,724 | $5K | |
| 70496 | <1% | 45 | $5K | |
| 0071A | <1% | 441 | $5K | |
| 97166 | <1% | 31 | $4K | |
| 84100 | <1% | 3,432 | $4K | |
| 85730 | <1% | 2,378 | $4K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 108 | $4K |
| 77290 | <1% | 77 | $4K | |
| 97802 | <1% | 69 | $4K | |
| 93351 | <1% | 13 | $4K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,785 | $4K |
| 74170 | <1% | 29 | $4K | |
| 93298 | <1% | 250 | $4K | |
| 96368 | <1% | 552 | $4K | |
| 73080 | <1% | 463 | $4K | |
| 81001 | <1% | 3,655 | $4K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,642 | $4K |
| 83880 | <1% | 1,206 | $4K | |
| 90715 | <1% | 2,077 | $3K | |
| 73552 | <1% | 278 | $3K | |
| 74018 | <1% | 295 | $3K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 543 | $3K |
| 74160 | <1% | 25 | $3K | |
| 73620 | <1% | 190 | $3K | |
| C1769 | Guide wire | <1% | 397 | $3K |
| 77295 | <1% | 15 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,376 | $3K |
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes | <1% | 21 | $3K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 67 | $3K |
| 72052 | <1% | 86 | $3K | |
| 85007 | <1% | 1,499 | $3K | |
| 83605 | <1% | 1,784 | $3K | |
| 80197 | <1% | 406 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 9,765 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 11,422 | $3K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,488 | $3K |
| 83615 | <1% | 1,485 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,724 | $3K |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 178 | $3K |
| 80354 | <1% | 618 | $3K | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 45 | $3K |
| 84702 | <1% | 1,153 | $2K | |
| 87522 | Neg quan hep c or qual rna | <1% | 337 | $2K |
| 93248 | <1% | 240 | $2K | |
| 78803 | <1% | 28 | $2K | |
| 73140 | <1% | 253 | $2K | |
| 97597 | <1% | 73 | $2K | |
| 73100 | <1% | 144 | $2K | |
| J9070 | Cyclophosphamide, 100 mg | <1% | 88 | $2K |
| 73090 | <1% | 469 | $2K | |
| 80061 | Lipid panel | <1% | 1,107 | $2K |
| 97602 | <1% | 93 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,611 | $2K |
| 93295 | <1% | 110 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,919 | $2K |
| 95812 | <1% | 28 | $2K | |
| 86923 | <1% | 175 | $2K | |
| 83690 | <1% | 2,939 | $2K | |
| 82728 | <1% | 657 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,673 | $2K |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 47 | $2K |
| 31575 | <1% | 30 | $2K | |
| 82570 | <1% | 596 | $2K | |
| 75635 | <1% | 12 | $2K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 3,288 | $2K |
| 86780 | <1% | 1,000 | $2K | |
| 73060 | <1% | 255 | $2K | |
| 93926 | <1% | 24 | $2K | |
| 77280 | <1% | 46 | $2K | |
| 99152 | <1% | 617 | $2K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 548 | $2K |
| 73070 | <1% | 127 | $2K | |
| 71101 | <1% | 211 | $2K | |
| 73200 | <1% | 27 | $1K | |
| 80076 | <1% | 1,639 | $1K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 704 | $1K |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 127 | $1K |
| 88112 | <1% | 138 | $1K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 439 | $1K |
| 82784 | <1% | 229 | $1K | |
| A9580 | Sodium fluoride f-18, diagnostic, per study dose, up to 30 millicuries | <1% | 16 | $1K |
| 90688 | <1% | 206 | $1K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 358 | $1K |
| 76641 | <1% | 16 | $1K | |
| J9206 | Injection, irinotecan, 20 mg | <1% | 49 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,024 | $1K |
| 90656 | <1% | 51 | $1K | |
| J3490 | Unclassified drugs | <1% | 10,498 | $1K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,776 | $1K |
| 83540 | <1% | 459 | $1K | |
| 85379 | <1% | 958 | $1K | |
| 87186 | <1% | 809 | $1K | |
| 84156 | <1% | 481 | $981.45 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,427 | $980.59 |
| 76825 | <1% | 13 | $972.51 | |
| 96523 | <1% | 69 | $955.88 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 816 | $908.20 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 397 | $863.20 |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 104 | $838.53 |
| 87077 | <1% | 916 | $819.40 | |
| 20552 | <1% | 13 | $758.25 | |
| 88307 | <1% | 388 | $757.00 | |
| 73600 | <1% | 55 | $731.49 | |
| 84153 | <1% | 94 | $723.07 | |
| 92523 | <1% | 12 | $704.54 | |
| 76937 | <1% | 256 | $678.44 | |
| 94727 | <1% | 30 | $676.03 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 28 | $662.34 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 86 | $655.51 |
| 93246 | <1% | 15 | $655.29 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 451 | $640.92 |
| 0012A | <1% | 14 | $636.40 | |
| 76942 | <1% | 52 | $635.07 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 5,972 | $628.37 |
| 83550 | <1% | 447 | $622.71 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,140 | $610.34 |
| 93325 | <1% | 13 | $585.42 | |
| 84550 | <1% | 213 | $577.84 | |
| 90686 | <1% | 124 | $572.31 | |
| 0011A | <1% | 67 | $554.40 | |
| J1815 | Injection, insulin, per 5 units | <1% | 3,373 | $549.59 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,280 | $531.13 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,512 | $512.85 |
| 88342 | <1% | 160 | $504.00 | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 16 | $481.91 |
| 82550 | <1% | 762 | $467.04 | |
| 82607 | <1% | 275 | $464.97 | |
| 90746 | <1% | 26 | $461.24 | |
| 87497 | <1% | 39 | $459.39 | |
| 85384 | <1% | 193 | $458.56 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 850 | $453.62 |
| 87070 | <1% | 530 | $423.52 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,826 | $410.42 |
| 83883 | <1% | 36 | $409.85 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 126 | $409.50 |
| 90662 | <1% | 47 | $408.28 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,082 | $407.51 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,152 | $405.85 |
| 88184 | <1% | 22 | $395.98 | |
| 72202 | <1% | 17 | $393.35 | |
| 77002 | <1% | 25 | $384.58 | |
| 87205 | <1% | 441 | $369.19 | |
| 86022 | <1% | 55 | $360.01 | |
| 72170 | <1% | 37 | $358.70 | |
| 76857 | <1% | 13 | $353.09 | |
| 70487 | <1% | 13 | $340.67 | |
| 87340 | <1% | 95 | $321.88 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,642 | $313.55 |
| 86140 | <1% | 548 | $309.89 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 15 | $290.86 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 358 | $279.31 |
| 82746 | <1% | 143 | $271.64 | |
| 80320 | <1% | 265 | $269.88 | |
| 73660 | <1% | 29 | $267.54 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 672 | $252.89 |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 60 | $237.30 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,393 | $227.48 |
| A9540 | Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries | <1% | 13 | $227.03 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 28 | $224.13 |
| 87400 | <1% | 107 | $218.52 | |
| 86334 | <1% | 32 | $206.79 | |
| 88309 | <1% | 78 | $206.52 | |
| 94644 | <1% | 126 | $201.40 | |
| 85651 | <1% | 181 | $200.86 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 186 | $195.95 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,156 | $192.74 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 708 | $179.33 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,078 | $177.18 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 41 | $176.69 |
| 88304 | <1% | 175 | $171.91 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 69 | $167.09 |
| 86706 | <1% | 27 | $165.94 | |
| 84439 | <1% | 135 | $162.89 | |
| 94760 | <1% | 395 | $155.13 | |
| 80368 | <1% | 74 | $147.52 | |
| 94799 | <1% | 149 | $146.78 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 29 | $144.00 |
| 82105 | <1% | 14 | $140.57 | |
| 88311 | <1% | 48 | $140.47 | |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | <1% | 197 | $140.30 |
| 93294 | <1% | 15 | $130.90 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 27 | $129.60 |
| 84165 | <1% | 67 | $123.62 | |
| 87075 | <1% | 94 | $112.26 | |
| 84132 | <1% | 76 | $110.64 | |
| 77001 | <1% | 13 | $109.97 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 489 | $102.43 |
| 81000 | <1% | 250 | $100.67 | |
| 94761 | <1% | 470 | $99.72 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,657 | $97.40 |
| 82248 | <1% | 27 | $96.78 | |
| 87210 | <1% | 264 | $96.46 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,673 | $90.04 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 29 | $87.90 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 859 | $75.12 |
| 80164 | <1% | 17 | $72.14 | |
| 99406 | <1% | 25 | $54.93 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 988 | $44.14 |
| 87081 | <1% | 115 | $41.24 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,458 | $41.02 |
| 87116 | <1% | 18 | $36.38 | |
| 94762 | <1% | 18 | $34.96 | |
| G0008 | Administration of influenza virus vaccine | <1% | 58 | $31.25 |
| 84155 | <1% | 32 | $29.79 | |
| 87102 | <1% | 15 | $27.65 | |
| 82330 | <1% | 13 | $26.20 | |
| 82013 | <1% | 15 | $25.87 | |
| 85018 | <1% | 37 | $24.55 | |
| 82043 | <1% | 29 | $23.87 | |
| 84478 | <1% | 35 | $20.49 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 64 | $18.34 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 346 | $17.84 |
| C1758 | Catheter, ureteral | <1% | 35 | $16.97 |
| 0064A | <1% | 67 | $16.60 | |
| 87206 | <1% | 19 | $14.55 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 16 | $13.65 |
| 80345 | <1% | 12 | $12.46 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 98 | $10.27 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,691 | $8.98 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 261 | $8.75 |
| 86870 | <1% | 12 | $8.45 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 1,549 | $7.18 |
| G9920 | Screening performed and negative | <1% | 1,048 | $4.01 |
| 86592 | <1% | 15 | $4.00 | |
| 82270 | <1% | 13 | $3.47 | |
| 88300 | <1% | 49 | $2.92 | |
| G9919 | Screening performed and positive and provision of recommendations | <1% | 228 | $0.43 |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | 0% | 80 | $0.00 |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | 0% | 1,145 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 141 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 301 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 37 | $0.00 |
| J2350 | Injection, ocrelizumab, 1 mg | 0% | 76 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 401 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 207 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 26 | $0.00 |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | 0% | 24 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 1,197 | $0.00 |
| Q5120 | Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg | 0% | 65 | $0.00 |
| 90375 | 0% | 14 | $0.00 | |
| J2305 | Injection, nitroglycerin, 5 mg | 0% | 12 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 13 | $0.00 |
| J2404 | Injection, nicardipine, 0.1 mg | 0% | 12 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 20 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 1,074 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 1,220 | $0.00 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 38 | $0.00 |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 0% | 54 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 284 | $0.00 |
| J9305 | Injection, pemetrexed, not otherwise specified, 10 mg | 0% | 101 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 164 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 34 | $0.00 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 298 | $0.00 |
| J9041 | Injection, bortezomib, 0.1 mg | 0% | 430 | $0.00 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 37 | $0.00 |
| J0741 | Injection, cabotegravir and rilpivirine, 2mg/3mg | 0% | 158 | $0.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 14 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 53 | $0.00 |
| 90791 | Psychiatric diagnostic evaluation | 0% | 55 | $0.00 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 17 | $0.00 |
| 88302 | 0% | 28 | $0.00 | |
| 0013A | 0% | 47 | $0.00 | |
| J3250 | Injection, trimethobenzamide hcl, up to 200 mg | 0% | 16 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 25 | $0.00 |
| 89051 | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSNYDER, CHRISTOPHER (CEO)
| Provider | Location | Paid |
|---|---|---|
| Temple University Hospital, INC - Psych Unit | Philadelphia, PA | $22.27M |
| Temple University Hospital, INC | Philadelphia, PA | $13.60M |
| Temple University Hospital, INC | Philadelphia, PA | $4.01M |
| CHH Community Health | Philadelphia, PA | $3.55M |
| Temple University Hospital, INC | Philadelphia, PA | $9K |
| Temple University Hospital, INC | Philadelphia, PA | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.